MSMerve Sumbul

Merve Sumbul

*This is an algorithmically generated author record based on publicly available information.

Merve Sumbul has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment-Intensity Associations of Atorvastatin Therapy with Albuminuria and Liver Stiffness in Patients with Type 2 Diabetes and Hyperlipidemia: The ALI-STAR Study

    by Dilan Damla Ozturk, Hilmi Erdem Sumbul, Erdinc Gulumsek, Cigdem Erhan, Bektas Isik, Cisem Yilmaz, Cahit Dincer, Ahmet Gazi Mustan, Irfan Alisan, Mevlut Koc, et al.

    Background/Objectives: Diabetic kidney disease (DKD) and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently coexist in patients with type 2 diabetes mellitus (T2DM) and share common pathophysiological mechanisms. Although atorvastatin has been investigated for potential renal and hepatic effects, real-world evidence regarding its associations with both renal and hepatic surrogate markers remains limited. This study investigated the association between atorvastatin therapy and longitudinal changes in urinary albumin-to-creatinine ratio (UACR) and liver stiffness measured by vibration-controlled transient elastography (VCTE) in patients with T2DM. Methods: This retrospective observational study included 612 patients with T2DM who were categorized into three groups according to atorvastatin treatment: no statin (n = 198), atorvastatin 10–20 mg/day (n = 205), and atorvastatin 40 mg/day (n = 209). UACR and liver stiffness were assessed at baseline and after six months. Between-group comparisons and multivariable linear regression analyses were performed to evaluate the independent association of atorvastatin therapy with changes in renal and hepatic surrogate markers. Results: Baseline UACR and liver stiffness were comparable among the three groups. During six months of follow-up, UACR increased in the no-statin group (+8.64 mg/g) but decreased significantly in the atorvastatin 10–20 mg (−27.68 mg/g) and 40 mg (−44.64 mg/g) groups (overall p < 0.001). Similarly, liver stiffness remained unchanged in the no-statin group (−0.02 kPa) but decreased by 0.42 kPa and 0.93 kPa in the atorvastatin 10–20 mg and 40 mg groups, respectively (overall p < 0.001). In multivariable models adjusted for baseline outcome values and relevant clinical covariates, both atorvastatin treatment groups remained significantly associated with lower six-month UACR and liver stiffness compared with the no-statin group (all p < 0.001). Conclusions: Atorvastatin treatment intensity was associated with differences in six-month UACR and liver stiffness in patients with T2DM, with numerically greater reductions observed in the 40 mg/day group. These observational findings are hypothesis-generating and require confirmation in prospective studies before causal or long-term clinical benefits can be established.

  • Open Access

    Changes in Symptoms and Lung Function During Three Months of Individually Tailored Inhaled Therapy in Chronic Obstructive Pulmonary Disease: A Prospective Observational Cohort Study

    by Bektas Isik, Hilmi Erdem Sumbul, Huseyin Ali Ozturk, Begum Seyda Avci, Erdinc Gulumsek, Merve Sumbul, Irfan Alisan, Ahmet Gazi Mustan, Fatih Necip Arici, Cisem Yilmaz, et al.

    Background. Randomised controlled trials have established what individual inhaled regimens can achieve in chronic obstructive pulmonary disease (COPD) under controlled conditions, but they recruit selected populations and enforce protocol-driven follow-up. How patients fare on regimens chosen individually for them in everyday care is less well characterised. Objective. To assess the change in symptoms and lung function over three months in a prospective cohort of patients with COPD whose inhaled treatment was tailored to the individual by the attending physician. Methods. Consecutive adults with stable, spirometrically confirmed COPD attending a single internal-medicine clinic were assessed at baseline and reassessed approximately three months later. Baseline regimens were short-acting beta2-agonist/short-acting muscarinic antagonist (SABA/SAMA), long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA), LABA plus inhaled corticosteroid (ICS), LABA plus LAMA, or LABA plus LAMA plus ICS. The primary outcomes were the within-participant change in COPD Assessment Test (CAT) score and in forced expiratory volume in one second (FEV1) % predicted. Secondary outcomes were the proportion achieving the CAT minimal clinically important difference (MCID, defined as a reduction of at least two points), the proportion achieving a six-minute walk distance (6MWD) improvement of at least 30 m, change in modified Medical Research Council (mMRC) dyspnoea grade, body mass index–airflow obstruction–dyspnoea–exercise capacity (BODE) and age–dyspnoea–obstruction (ADO) indices, and clinical events. Paired changes were analysed with paired t-tests or Wilcoxon signed-rank tests and are reported with 95% confidence intervals (CIs). Results. Three hundred participants were enrolled. Recorded GOLD groups were A (n = 69), B (n = 158) and E (n = 73). Paired CAT and FEV1 data were available for 276 (92.0%) and 257 (85.7%) participants, all of whom were reassessed between 84 and 98 days after baseline (median 91 days). Across the cohort, mean CAT fell by 3.93 points (95% CI −4.43 to −3.44) and mean FEV1 rose by 2.20 percentage points (95% CI 1.78 to 2.63); one hundred and ninety-five of 276 participants (70.7%) reached the CAT MCID and 98 of 244 (40.2%) achieved a 6MWD gain of at least 30 m. Improvement was observed with every long-acting regimen. Participants receiving LABA + ICS improved by 4.18 CAT points (95% CI −5.24 to −3.12; p < 0.001) and 3.06 FEV1 percentage points (95% CI 2.16 to 3.95; p < 0.001), with 82.1% reaching the CAT MCID—a magnitude similar to that observed on LABA+LAMA. Participants on SABA/SAMA alone showed no improvement in either outcome. Sixty-three exacerbations, eleven hospitalisations and four cases of pneumonia occurred. Conclusions. During a reassessment interval of 84 to 98 days, patients with COPD receiving individually tailored long-acting inhaled therapy showed improvement in symptoms and lung function that exceeded the established MCID for the CAT, including patients treated with LABA+ICS. The study had no concurrent control group, no randomisation and no adjustment for baseline differences between regimens; the observed changes therefore describe the course of treated patients and cannot be attributed to any specific regimen.

  • Open Access

    Real-world treatment gaps in hypertension management: drug switching, prescribing patterns and apparent resistant hypertension – a retrospective observational study

    by Hilmi Erdem Sumbul, Ahmet Gazi Mustan, Bektas Isik, Huseyin Ali Ozturk, Fatih Necip Arici, Begüm Seyda Avci, Erdinc Gulumsek, Merve Sumbul, Dilan Damla Ozturk, Irfan Alisan, et al.

  • Open Access

    Diabetic Retinopathy Grading and Concurrent Cardiorenal Biomarker Abnormalities in Type 2 Diabetes: Albuminuria and Elevated NT-proBNP—A Retrospective Cross-Sectional Study

    by İrfan Alisan, Ahmet Gazi Mustan, Bektas Isik, Fatih Necip Arıcı, Cahit Dinçer, Çisem Yılmaz, Mehmet Erdevir, Ahmet Altıntaş, Çiğdem Erhan, Merve Saracoglu Sumbul, et al.

    Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a recognised marker of systemic vascular injury. Whether DR—graded independently by two experienced ophthalmologists as part of routine institutional care—is independently associated with concurrent nephropathy (urine albumin-to-creatinine ratio [UACR] ≥ 30 mg/g) and subclinical cardiac stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥ 125 pg/mL) remains insufficiently examined. Methods: Retrospective cross-sectional study of 401 T2DM adults who underwent dilated fundus examination independently graded by two board-certified ophthalmologists (each ≥ 10 years’ experience in diabetic eye disease) using ETDRS-based classification. Inter-physician agreement was quantified by Cohen’s weighted kappa. The primary composite outcome was concurrent nephropathy and subclinical cardiac stress. Multivariable logistic regression adjusted for age, sex, HbA1c, diabetes duration, eGFR, hypertension, and pharmacological treatments. Results: The composite outcome was present in 120 (64.2%) DR-positive vs. 14 (6.5%) DR-negative patients (crude OR: 25.59 (13.78–47.51); p < 0.001; fully adjusted OR: 21.49 (11.02–41.81); p < 0.001). Inter-physician agreement was high (Cohen’s weighted κ = 0.88; 95% CI: 0.83–0.93). Nephropathy alone was found in 164 (87.7%) vs. 76 (35.5%) patients (OR: 12.95 (7.71–21.75); p < 0.001), and elevated NT-proBNP in 137 (73.3%) vs. 39 (18.2%) patients (OR: 12.29 (7.65–19.76); p < 0.001). A significant trend across DR severity grades was observed (p for trend < 0.001), although the gradient was not strictly monotonic. ROC AUC = 0.837 (95% CI: 0.784–0.860). Conclusions: Ophthalmologist-graded DR was independently associated with the concurrent presence of albuminuria and elevated NT-proBNP in T2DM. Because the design is cross-sectional, these findings describe association rather than prediction or causation. They generate the hypothesis that retinal grading may help flag patients in whom cardiorenal biomarker assessment is worth considering, but prospective validation is required before any screening application.

  • Open Access

    Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study

    by Hilmi Erdem Sumbul, Bektas Isik, Ahmet Gazi Mustan, Irfan Alisan, Cigdem Erhan, Fatma Inci Koca, Aysenur Ucar, Mehmet Erdevir, Begum Seyda Avci, Merve Saracoglu Sumbul, et al.

    Background: Several studies have demonstrated that adding semaglutide to the treatment of patients with type 2 diabetes mellitus (T2DM) reduces insulin requirements and glycated hemoglobin (HbA1c) levels. This study aimed to investigate real-world evidence for the effects of semaglutide dose escalation on HbA1c, body weight, dyslipidemia, and insulin dose reduction in patients with T2DM in the Cukurova region of Türkiye. Methods: This retrospective cohort study enrolled 500 patients (255 male, 245 female; mean age 56.1 ± 10.8 years) who initiated semaglutide therapy for T2DM between 2024 and 2025. Patients were grouped according to their maximum semaglutide dose: 0.25 mg (Group I), 0.50 mg (Group II), and 1.00 mg (Group III). The primary endpoint was the change in HbA1c from baseline to end of study (30 weeks) across semaglutide dose escalation groups. Secondary endpoints included changes in body weight, frequency of insulin dose reduction, and effects on lipid parameters. Results: A total of 117 patients (23.4%) discontinued semaglutide therapy, while 383 patients (76.6%) completed the study. The primary endpoint revealed a mean HbA1c reduction of −1.03 ± 0.35% from baseline to end of study (95% CI 0.99–1.07; t = 58.644; p < 0.001). Reductions in HbA1c increased progressively from Group I to Group III (HbA1c: −0.72 ± 0.28, −1.02 ± 0.26, −1.27 ± 0.34%). Insulin dose reduction frequency increased significantly from Group I to Group III (40%, 41%, and 51%, respectively; p = 0.010), with a statistically significant difference only between Group I and Group III. At the end of follow-up, rates of hypoglycemic episodes and gastrointestinal (GI) adverse events were similar across groups. Conclusions: In a real-world population from the Cukurova region of Türkiye, semaglutide dose escalation in T2DM patients achieved clinically meaningful glycemic control, body weight reduction, LDL-cholesterol lowering, and a significant increase in insulin dose reduction frequency, without a significant increase in GI adverse events.

  • Epistaksis Yönetimi

    by Merve Sümbül

    Aile Hekimliğinde Akut Hastalıkların Yön.Cilt:1-2

  • Aile Hekimliğinde Akut Hastalıkların Yönetimi Cilt 1 ve Cilt 2

    by Yasemin Özkan Aksungur, Beyza Akçal, Ersin Akpınar, Ceyhun Yurtsever, Fatma Gökşin Cihan, Zerrin Gamsızkan, Esra Çelik, Nazlı Şensoy, Tansu Çevik, Dilara Canbay Özdemir, et al.

    Akut hastalık yönetimi, sağlık hizmetlerinin en kritik ve en hızlı karar verme gerektiren alanlarından biridir. Zamanla yarışılan bu süreçte doğru tanıya hızla ulaşmak, uygun tedaviyi başlatmak ve gerektiğinde doğru yönlendirmeyi yapmak, birinci basamak sağlık hizmetlerinin etkinliğini belirleyen temel unsurlardır. Aile Hekimliğinde Akut Hastalıkların Yönetimi, sahada karşılaşılan gerçek klinik gereksinimlerden doğmuş; sistematik, uygulanabilir ve güncel bir başvuru kaynağı olarak hazırlanmıştır. Aile hekimliği ilkeleri doğrultusunda yapılandırılan bu eser, akut hastalıklara yalnızca biyomedikal açıdan değil, biyopsikososyal ve kültürel boyutlarıyla bütüncül bir yaklaşım sunmaktadır. Kitap; ayrışmamış hastaya yaklaşım, hızlı ve doğru klinik karar verme, belirsizliklerin yönetimi ve sevk-izlem dengesi gibi birinci basamak pratiğinin temel zorluklarına rehberlik etmektedir. Aynı zamanda hasta merkezli bakım, etkili iletişim, etik ilkeler ve hasta güvenliği gibi modern tıbbın vazgeçilmez unsurlarını akut bakım süreçleriyle bütünleştirmektedir. Tele-tıp uygulamaları, dijital sağlık araçları ve elektronik sağlık kayıtları gibi güncel yaklaşımlar da eserde pratik bir perspektifle ele alınmaktadır. Klinik içerik açısından ise solunum, gastrointestinal, üriner ve genital, kas-iskelet, travmaya bağlı akut durumlar, kardiyovasküler, nörolojik, dermatolojik, göz, kulak, burun ve boğaz pediatrik, kadın sağlığı ve gebelik, geriatrik ve kırılgan popülasyon, psikiyatrik, metabolik ve endokrin, hematolojik, afetler ve olağanüstü durumlardaki tüm akut hastalıkları, kanıta dayalı ve sahada uygulanabilir bir çerçevede sunulmaktadır.

  • Open Access

    The relationship between serum galectin-3 level and echocardiographic findings in patients with polycystic ovary syndrome

    by Ibrahim Erdem, Huseyin Ali Ozturk, Erdinc Gulumsek, Fatih Necip Arici, Begum Seyda Avci, Cigdem Erhan, Dilan Damla Ozturk, Merve Saracoglu Sumbul, Hilmi Erdem Sumbul

    In the our study, we examined the relationship between galectin-3 levels and global longitudinal strain (GLS) and aortic intima-media thickness (A-IMT) in

  • Open Access

    Vaccination status as a determinant of hospitalization in influenza: Insights from emergency department data

    by Merve Saracoglu Sumbul, Mehmet Can Erisen, Berçem Berent Kaya, Hilmi Erdem Sumbul, Ramazan Azim Okyay, Burhan Fatih Kocyigit

    Purpose: This study aims to investigate the effect of seasonal influenza vaccination on hospitalization rates among patients presenting to the emergency department with influenza-like illness. Methods: A retrospective, single-center observational study was conducted, involving adult patients with influenza (ICD-10 codes J10 and J11) diagnosed in the emergency department between May 2024 and April 2025. Clinical and demographic information was collected from electronic records, and vaccination status was confirmed through follow-up phone calls. To tackle the “zero event” problem—no hospitalizations among vaccinated individuals—advanced statistical modeling was employed, including standard logistic regression, and Bayesian logistic regression using Markov Chain Monte Carlo (MCMC) simulations. Odds ratios (OR) and 95% Highest Density Intervals (HDI) were calculated to assess the effectiveness of vaccination. Results: A total of 878 patients were enrolled: 3.3% ( n = 29) received vaccinations, while 2.7% ( n = 24) required hospitalization. None of the vaccine recipients were hospitalized. Standard logistic regression indicated that age was a significant indicator of hospitalization. Furthermore, Bayesian logistic regression followed, which confirmed vaccination’s statistically significant protective effect. The OR for vaccination was 0.526 (95% HDI: 0.336–0.739), indicating a 47% reduction in hospitalization risk among vaccinated individuals. Conclusion: Seasonal influenza vaccination was significantly associated with a lower risk of hospitalization in patients presenting with influenza-like illness to the emergency department. These findings support public health initiatives to enhance influenza vaccine coverage, particularly for the elderly.